ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Aera Therapeutics has launched with $193 million in series A and B funding led by Arch Venture Partners, GV, and Lux Capital. The start-up aims to widen the reach of genetic medicines and enable the delivery of these therapies to tissues in the body beyond those in the liver. Aera’s technology uses human protein nanoparticles as the delivery vehicle for genetic material, an approach developed in the lab of its founder, Feng Zhang, a professor at MIT and a CRISPR pioneer.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X